雌激素受体阳性乳腺癌患者内分泌耐药机制的研究进展

doi:10.13481/j.1671-587x.20170248

摘要/Abstract

摘要： 内分泌治疗在雌激素受体阳性（ER+）乳腺癌治疗中占有重要地位。随着内分泌治疗的发展，内分泌治疗耐药（原发性耐药和继发性耐药）成为亟待解决的问题。国内外均对乳腺癌内分泌耐药进行了大量的基础研究和临床试验，亦有较多综述报道，但均纵向介绍某一种耐药机制或某一类药物的耐药机制。本文对ER+乳腺癌内分泌耐药机制的研究现状进行全面综述，探讨ER+乳腺癌内分泌耐药治疗的最新进展。

关键词: 乳腺肿瘤, 内分泌耐药, 临床试验, 雌激素受体

中图分类号:

R730.5

何悦铭, 康丽花, 王倩, 王迦南, 宋艳秋. 雌激素受体阳性乳腺癌患者内分泌耐药机制的研究进展[J]. 吉林大学学报(医学版), 2017, 43(02): 454-458.

[1] GradisharW, Salerno KE. NCCN Guidelines Update:Breast Cancer[J].J Natl Compr Cancer Netw, 2016,14(5 Suppl):641-644.
[2] AndreF, Slimane K, Bachelot T, et al.Breast cancer with synchronous metastases:trends in survival during a 14-year period[J].J Clin Oncol,2004,22(16):3302-3308.
[3] Buzdar AU.Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J].J Clin Oncol, 2004,22(15):3199-3200.
[4] Abraham JE, Maranian MJ, Driver KE, et al.CYP2D6 gene variants:association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen[J].Breast Cancer Res,2010,12(4):R64.
[5] Binkhorst L, Mathijssen RH, Jager A, et al.Individualization of tamoxifen therapy:much more than just CYP2D6 genotyping[J].Cancer Treat Rev,2015,41(3):289-299.
[6] Clarke R, Tyson JJ, Dixon JM.Endocrine resistance in breast cancer-An overview and update[J].Mol Cellular Endocrinol, 2015,418 Pt3:220-234.
[7] O'Sullivan CC.Overcoming Endocrine Resistance in-hormone-receptor positive advanced breast cancer-The emerging role of CDK4/6 inhibitors[J].Int J Cancer Clin R,2015,2(4):29.
[8] Ferraldeschi R, Arnedos M, Hadfield KD, et al.Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients[J].Breast Cancer Res Treat, 2012,133(3):1191-1198.
[9] Stephens PJ, Tarpey PS, Davies H, et al.The landscape of cancer genes and mutational processes in breast cancer[J].Nature,2012,486(7403):400-404.
[10] Cardoso F, Costa A, Norton L, et al.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)[J].Breast, 2014,23(5):489-502.
[11] Parbin S, Kar S, Shilpi A, et al.Histone deacetylases:a saga of perturbed acetylation homeostasis in cancer[J].J Histochem Cytochem, 2014,62(1):11-33.
[12] Yardley DA, Ismail-Khan RR, Melichar B, et al.Randomized phase Ⅱ, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor[J].J Clin Oncol,2013,31(17):2128-2135.
[13] Jordan VC, Curpan R, Maximov PY.Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators[J].J Nat Cancer Inst, 2015,107(6):djv075.
[14] Ma CX, Adjei AA, Salavaggione OE, et al.Human aromatase:gene resequencing and functional genomics[J].Cancer Res,2005,65(23):11071-11082.
[15] Bolden JE, Peart MJ, Johnstone RW.Anticancer activities of histone deacetylase inhibitors[J].Nat Rev Drug Discov, 2006,5(9):769-784.
[16] Hanahan D, Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[17] DeGraffenried LA, Fulcher L, Friedrichs WE, et al.Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway[J].Ann Oncol,2004,15(10):1510-1516.
[18] Kaufman B, Mackey JR, Clemens MR, et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
[19] Johnston S, Pippen J, Pivot X, et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol, 2009,27(33):5538-5546.
[20] Yardley DA, Noguchi S, Pritchard KI, et al.Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:BOLERO-2 final progression-free survival analysis[J].Adv Ther, 2013,30(10):870-884.
[21] Bachelot T, Bourgier C, Cropet C, et al.Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study[J].J Clin Oncol, 2012,30(22):2718-2724.
[22] Wolff AC, Lazar AA, Bondarenko I, et al.Randomized phase Ⅲ placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J].J Clin Oncol, 2013,31(2):195-202.
[23] Shapiro GI, Rodon J, Bedell C, et al.Phase Ⅰ safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class Ⅰ PI3K inhibitor, in patients with advanced solid tumors[J].Clin Cancer Res, 2014,20(1):233-245.
[24] Sarker D, Ang JE, Baird R, et al.First-in-human phase Ⅰ study of pictilisib (GDC-0941), a potent pan-class Ⅰ phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors[J].Clin Cancer Res, 2015,21(1):77-86.
[25] Maira SM, Pecchi S, Huang A, et al.Identification and characterization of NVP-BKM120, an orally available pan-class Ⅰ PI3-kinase inhibitor[J].Mol Cancer Ther, 2012,11(2):317-328.
[26] Mauro L, Pellegrino M, Giordano F, et al.Estrogen receptor-alpha drives adiponectin effects on cyclin D1 expression in breast cancer cells[J].FASEB J, 2015,29(5):2150-2160.
[27] Lundgren K, Brown M, Pineda S, et al.Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen:a TransATAC study[J].Breast Cancer Res,2012,14(2):R57.
[28] Giessrigl B, Schmidt WM, Kalipciyan M, et al.Fulvestrant induces resistance by modulating GPER and CDK6 expression:implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex[J].Br J Cancer, 2013,109(10):2751-2762.
[29] Finn RS, Crown JP, Lang I, et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):a randomised phase 2 study[J].Lancet Oncol, 2015,16(1):25-35.
[30] Cristofanilli M, Turner NC, Bondarenko I, et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3):final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J].Lancet Oncol, 2016,17(4):425-439.
[31] Herynk MH, Fuqua SA.Estrogen receptor mutations in human disease[J].Endocr Rev,2004,25(6):869-898.
[32] Toy W, Shen Y, Won H, et al.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J].Nat Genet,2013,45(12):1439-1445.
[33] Jeselsohn R, Yelensky R, Buchwalter G, et al.Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer[J].Clin Cancer Res,2014,20(7):1757-1767.
[34] Robinson DR, Wu YM, Vats P, et al.Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J].Nat Genet, 2013,45(12):1446-1451.
[35] Andre F, Bachelot T, Commo F, et al.Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer:a multicentre, prospective trial (SAFIR01/UNICANCER)[J].Lancet Oncol, 2014,15(3):267-274.
[36] Robertson JF, Llombart-Cussac A, Rolski J, et al.Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study[J].J Clin Oncol, 2009,27(27):4530-4535.
[37] Di Leo A, Jerusalem G, Petruzelka L, et al.Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J].J Clin Oncol, 2010,28(30):4594-4600.
[38] Robertson JF, Bondarenko IM, Trishkina E, et al.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON):an international, randomised, double-blind, phase 3 trial[J].Lancet,2016,388(10063):2997-3005.

雌激素受体阳性乳腺癌患者内分泌耐药机制的研究进展

Progress research on mechanism of endocrine resistance in patients with estrogen receptor positive breast cancer

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 10

[1]	冯少青,孟峻. 血清和糖皮质激素诱导蛋白激酶3与肿瘤发生发展关系的研究进展Research progress in relationship between serum and glucocorticoid-induced protein kinase 3 and occurrence and development of tumor[J]. 吉林大学学报(医学版), 2022, 48(2): 540-545.
[2]	于秀艳,李铤,丛占杰,王文龙,张晓伟,吴雪峰. 乳腺癌患者外周血中hMAM、SBEM和CEACAM19 mRNA联合检测及其临床意义[J]. 吉林大学学报(医学版), 2022, 48(1): 195-202.
[3]	于秀艳,田春迎,张晓伟,吴雪峰. 血清SBEM、hMAM和CEACAM19水平在乳腺癌早期诊断中的临床意义[J]. 吉林大学学报(医学版), 2021, 47(6): 1518-1525.
[4]	于洋,刘赛男,刘云恺,李勇,乔乙春,程熠. PRPS2表达特点及其与乳腺癌预后关系的生物信息学分析[J]. 吉林大学学报(医学版), 2021, 47(5): 1229-1236.
[5]	毛天娇,孙铎,高幸,魏溦,李熙恒,姜可新,姜秋,李江. 人参皂苷Rh1对MC3T3-E1细胞增殖和分化的促进作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(4): 896-903.
[6]	巩培, 刘竟然, 赵世敏, 王玉珍, 谢基明. MCM10沉默对乳腺癌MDA-MB-231细胞的增殖抑制作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 652-659.
[7]	王青,解思琦,郑凯,唐一吟,李红万,张恒瑀,谭明建,彭蕾,刘德权,唐诗聪. 接受不同化疗方案乳腺癌患者血清B族维生素水平检测及其临床意义[J]. 吉林大学学报(医学版), 2021, 47(3): 724-730.
[8]	唐浩轩,孟楠峰,杜美玲,王伟,何涛. 新型VEGF单克隆抗体与全反式维甲酸联合应用对乳腺癌MCF-7细胞增殖的抑制作用[J]. 吉林大学学报(医学版), 2021, 47(2): 344-351.
[9]	黄果,王佑权,陈娟. miRNA-138-5p靶向抑制HIF-1α表达对乳腺癌MCF-7细胞顺铂耐药的逆转作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(2): 360-368.
[10]	孔雯聪, 贺武斌, 苏荣健, 贾答淇, 谷艳娇, 王月, 杜晓媛. MST1R抑制剂BMS-777607对乳腺癌MCF-7细胞增殖的抑制和凋亡诱导作用[J]. 吉林大学学报(医学版), 2020, 46(03): 451-457.
[11]	徐凤英, 刘儒, 马丽, 曲一帆, 肖伟利, 王玉珍, 谢基明. 乳腺癌MDA-MB-231细胞中Rab7a基因的网络分析[J]. 吉林大学学报(医学版), 2020, 46(03): 464-469.
[12]	冯磊, 张韩特, 李响, 孟繁平, 李妍. IL-4协同雌二醇对小鼠乳腺癌细胞生长的促进作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(03): 536-542.
[13]	申李胜男, 李思敏, 李倩, 麻帅, 韩冰. 拉曼光谱技术在乳腺癌临床应用方面的研究进展[J]. 吉林大学学报(医学版), 2020, 46(02): 413-418.
[14]	陈州华, 龚辉, 冯磊, 肖玉洁, 黄立中. LPS对乳腺癌MDA-MB-231细胞上皮间质转化的诱导作用及其对β-catenin表达的影响[J]. 吉林大学学报(医学版), 2020, 46(02): 309-315.
[15]	周春, 王光华, 张帮柱. miR-367对人乳腺癌MCF-7细胞增殖、侵袭和迁移的影响及其机制[J]. 吉林大学学报(医学版), 2019, 45(06): 1353-1360.